Cosmo Pharmaceuticals N.V. Stock: price and insider trades · Switzerland

Cosmo Pharmaceuticals N.V., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SIX SER. From 18 October 2025 to 18 October 2026, the disclosure feed for Cosmo Pharmaceuticals N.V. logged 59 filings by 4 insiders.

Open-market activity splits into 21 purchases totalling €6.1M and 38 sales totalling €20.6M; 2 insiders sit on the buying side and 4 insiders on the selling side. The amount is not disclosed for 2 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 2 senior executives. The filings include the largest purchase, €4.0M, on 16 December 2025.

The data flag 17 purchases as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The clock since the last published purchase (9 March 2026) now reads 223 days. Most trades are made public on the day they happen. That lag is the time during which only the insider knows about the trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.

Compared with its exchange (178 companies, median 9 filings), a count of 59 filings is above the norm. Looking back to 2024, when coverage begins, insiders filed 25 purchases and 39 sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from SIX SER disclosures alone and does not predict where the share price will go.